SCHEMBL14699488

SCHEMBL14699488

COC(=O)C(C(=O)OC(C)(C)C)[C@H](N)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
LTA4H P09960 4/20 0.51
EPOR P19235 1/20 0.47
ALOX5 P09917 1/20 0.46
MAOB P27338 2/20 0.45
PTGES O14684 1/20 0.45
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
NR4A2 P43354 1/20 0.44
YAP1 P46937 1/20 0.44
ACACB O00763 1/20 0.44
SMPD1 P17405 1/20 0.44
GPR132 Q9UNW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14699489 1.00 KMT2A (0.55) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL16178662 0.86 KMT2A (0.47) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL16178663 0.86 KMT2A (0.47) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL14699537 0.85 KMT2A (0.47) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL14699539 0.85 KMT2A (0.47) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL14699538 0.83 KMT2A (0.46) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL16188945 0.82 KMT2A (0.44) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL3609023 0.81 KMT2A (0.64) KMT2ASMN1; SMN2LTA4HEPORALOX5
SCHEMBL28115743 0.81 KMT2A (0.67) KMT2ASMN1; SMN2ALOX5MAOBNR4A2
SCHEMBL28115744 0.81 KMT2A (0.67) KMT2ASMN1; SMN2ALOX5MAOBNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9744252-B2 Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi PIRAMAL IMAGING SA (CH) 2017-08-29 US disclosed
EP-2744802-B1 COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI PIRAMAL IMAGING SA (CH) 2017-01-04 EP disclosed
US-9345793-B2 Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi PIRAMAL IMAGING SA (CH) 2016-05-24 US disclosed
US-20160137629-A1 COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI PIRAMAL IMAGING SA (CH) 2016-05-19 US disclosed
US-20140314669-A1 COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI PIRAMAL IMAGING SA (CH) 2014-10-23 US disclosed
EP-2744802-A1 COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI Piramal Imaging SA (CH) 2014-06-25 EP disclosed
WO-2013023795-A1 COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI PIRAMAL IMAGING SA (CH) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140314669-A1 COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI F13B, FGB, SELPLG KMT2A 4576/4885SMN1; SMN2 4795/4885LTA4H 1100/4885
US-20160137629-A1 COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI F13B, FGB, SELPLG KMT2A 4576/4885SMN1; SMN2 4795/4885LTA4H 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.